In July 2004, two individuals developed blisters after the destruction of a WWl-era munition. To determine the causative agent, urine samples were collected from both the highly blistered patient (patient 1; 6.5% of total body surface area) and patient 2, who had only one small blister. Their urine was analyzed for metabolites of known vesicants including sulfur mustard (HD), Lewisite (L1), and nitrogen mustards. The urine samples only tested positive for metabolites of HD. Additional metabolites were measured to confirm the exposure of sulfur mustard agent HD, including thiodiglycol (TDG), TDG-sulfoxide, and the bismercapturate of mustard sulfone. On day 2 after the exposure, patient I had a lS-lyase metabolite level of 41 ng/mL, and patient 2 had a level of 2.6 ng/mt. Detectable levels of the ~-Iyase metabolite were observed in patient 1 for 11 days and in patient 2 for 7 days. Levels of TDG and both TDG and its sulfoxide measured together in the urine of patient 1 were found to be 24 ng/mL and 50 ng/mL, respectively, on day 2. The bis-mercapturate of mustard sulfone was detected in patient 1 (3.1 ng/mL) on day 2 but was not detected in samples taken on subsequent days.
Introduction

Materials and Methods
Sulfur mustard (HD) [2,2'-dichloroethyl sulfide] was first used as a chemical warfare agent during World War I (1). It is a powerful vesicant and a potent biological alkylating agent. HD has been contained in the arsenals of various countries since it was first used in 1917; its use in battle was most recently confirmed when employed by Iraq during the Iran-Iraq War (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1). HD is a Schedule I compound on the Chemical Weapons Convention Schedule of Chemicals (2) . Many nations are believed to have large stockpiles of the agent, and old shells and containers of HD are still a threat to human health.
Materials
All solvents and reagents were analytical grade. Dichloromethane was purchased from Tedia (Fairfield, OH). Acetonitrile, the reagent TiCI3 (titanium(III) chloride), approxiately 10 wt.% solution in 20-30 wt.% hydrochloric acid), N-ethyldiethanolamine (EDEA), N-methyldiethanolamine (MDEA), triethanolamine (TEA), TDG, heptafluorobutyric anhydride (HFBA), and all other chemicals, unless otherwise indicated, were from Sigma-Aldrich (St. Louis, MO). Sodium hydroxide was purchased from Caledon Laboratories (Georgetown, ON, Canada). Analytical standards and isotopically labeled standards for SBMTE and chlorovinylarsonous acid (CVAA) were not commercially available and were synthesized by Los Alamos National Laboratory (Los Alamos, NM). Research-grade helium and argon gases were obtained from Airgas (Radnor, PA), and instrument-grade isobutane gas was obtained from Specialty Gas Concepts (Pearland, TX). All gases used for gas chromatography-tandem mass spectrometry (GC-MS-MS) had a minimum purity of 99.999%. The 13C 4-TDG, 13C4-MDEA, 13C4-EDEA, and 13C6-TEA were obtained from Cambridge Isotope Labs (Andover, MA). ChemElut TM columns were purchased from Varian (Harbor City, CA), and Oasis HLB 6-mL solid-phase extraction (SPE) cartridges were purchased from Waters (Milford, MA).
Human samples
Ten daily spot urine samples were collected from Patient 1 starting on day 2 after the exposure, and then three weekly samples were taken 4, 5, and 6 weeks after the exposure. For patient 2, spot urine samples were collected on days 2, 4 and 7 after exposure. Detailed information on patients, the exposure scenario, and case history have been previously published (9, 10) .
Analysis of urine for TDG and TDG-sulfoxide as TDG
Sample preparation.
The method used to analyze these samples was similar to our previously published method (11) . It measured both TDG and TDG-sulfoxide together by reducing the sulfoxide to TDG. Briefly, each analytical run consisted of unknown samples, a urine blank, two quality control (QC) samples (one high, one low), and a complete calibration standard set. All standards, unknown urine samples, and QC samples were prepared identically, except where indicated, so that each sample underwent the entire sample preparation process. Urine samples (500 IJL) were spiked with 10 ng each of 13C4-TDG. An equal volume (500 pL) of ~-glucuronidase solution (type H1 from Helix pomatia; 1.16 mg/mL in 0.1M sodium acetate buffer, pH 5.0) was added to each sample, and the mixture was incubated overnight at 37~ A 1-mL aliquot of TIC13 was added to each sample, and the mixture was incubated at 75~ for I h. Samples were cooled to room temperature and 1 mL 10N NaOH was added.
The samples were mixed and centrifuged at 4000 rpm for 10 min. The supernatant was transferred to a new tube and centrifuged again. Oasis HLB SPE cartridges were pre-conditioned with 2 mL of methanol, then re-equilibrated with 4 mL H20. The particulate-free supernatant from the centrifuged urine sample was applied to the cartridges. The cartridges were washed with 2 mL H20, dried for 15 rain under vacuum, then were eluted with 3 mL methanol. The eluates were dried in a Turbovap | evaporator (Zymark, Hopkinton, MA) with 10 psi nitrogen at 50~ The residue was reconstituted in 200 lJL acetonitrile to which 20 pL HFBA was added. These samples were incubated at 50~ for 30 rain. Excess HFBA was quenched by adding 3 mL 0.1M sodium phosphate in 0.5M NaCI buffer (pH 10.0). The samples were extracted twice with 3 mL dichloromethane, dried under nitrogen at 30~ and reconstituted in 30 pL toluene. Argon was applied over the samples before capping to prevent the loss of TDG to oxidation. From the final extract, 1 IJL was injected for GC-MS-MS analysis.
GC-MS-MS analysis.
All MS analyses were performed with positive chemical ionization on a TSQ-7000 (ThermoFinnigan, San Jose, CA) coupled to a Trace GC (ThermoQuest, Austin, TX). The GC was fitted with a DB-5MS analytical column (J&W Scientific, Folsom, CA) with the following dimensions: 30-m length, 0.25-mm internal diameter, and 0.25-IJm film thickness. Helium (15-psi head pressure) was used as carrier gas, with splitless injections using a surge time and duration of 0.75 min and a surge pressure of 35 psi. The injector and transfer-line temperatures were 250~ and 260~ respectively. The initial GC oven temperature was 90~ and held for 2 rain, followed by a linear ramp at 50~ to 250~ which was held for 3 rain. The filament was operated at 200 eV, with an emission current of 300 IIA. The source temperature was 150~ Methane was used as a reagent gas (1500 reTort). Two precursor-to-product ion pairs were monitored in the positive ion mode for each analyte and its isotopically labeled internal standard using a multiple-reaction monitoring ( 
Analysis of urine for thiodiglycol only
Urine samples were analyzed for TDG in a similar fashion, except the TIC13 reduction steps were omitted. The solid-phase extraction, derivatization, and GC-MS-MS were all as described in the analysis of TDG and TDG-sulfoxide.
Analysis of urine for 15-1yase metabolites
Urine was treated with TiCI3 to reduce SBMSE and MSMTESE to SBMTE so that the three possible metabolites could be analyzed as a single analyte. The method used was the same as previously published (12) .
Sample preparation. A typical sample set included eight calibration standards, unknown urine samples, a urine blank, and two QC samples (1 ng/mL and 20 ng/mL). Urine samples (0.5 mL each) were dispensed into 15-mL screw-cap glass culture tubes and a 20-1~L aliquot of the 1-pg/mL internal standard stock solution was added to each tube to give an internal standard concentration of 40 ng/mL. TIC13 (1 mL) was added to the urine samples and they were incubated for I h at 75~ to induce reduction. A 2-mL volume of 6N sodium hydroxide was added, and the samples were well mixed using a multiposition vortex mixer. The addition of the base resulted in the precipitation of most of the titanium as TiO2. The samples were centrifuged at 4000 rpm for 5 rain, and the supernatant was poured directly onto the 3-mL Chem Elut columns, leaving the precipitated TiO2 behind. Samples were immediately eluted from the columns by the addition of 16 mL of dichloromethane/acetonitrile (3:2). The eluates containing SBMTE were collected in 15-mL conical tubes. The eluates were then evaporated to dryness in the TurboVap LV evaporator at 40~ The nitrogen pressure was initially adjusted to between I and 5 psi and was increased to 15-20 psi as the solvent volume decreased. Evaporation took about 20 min. Samples were reconstituted by adding 20 lJL of toluene, mixed with a vortex mixer, and transferred to autosampler vials for GC-MS-MS analysis.
GC-3'IS-MS analysis.
The mass spectral analyses were performed on a Finnigan TSQ-7000 triple-quadrupole MS, that was interfaced to a Trace GC. Injection was automated using the A200S autosampler (Finnigan MAT, San Jose, CA). The GC column was a 30-m DB-5MS capillary column (0.25-ram i.d., 0.25-pro film thickness, J&W Scientific). Sample injection was in the splitless and the surge modes using a 3-mm internal diameter single gooseneck glass liner. Surge pressure was set at 43.5 psi for 2.0 min. The injector temperature was 280~ Thermogreen LB-2 17-mm conditioned septa (Supelco, Bellefonte, PA) were used to ensure no degradation of the inlet septa at the high temperature profile. The helium carrier gas flow was set at I mL/min. Injection volume was 1 I~L. The GC temperature profile was as follows. The initial oven temperature was 90~ and held for 2.0 rain, followed by a ramp to 320~ at 70~
and finally held at 320~ for 3 rain. with isobutane as the reagent gas at a source pressure of 1.5 T (However, setting it to about 0.9 T for tuning the MS with FC43 was necessary because the higher isobutane pressure caused too many background mass peaks.) Argon was used as the collision gas for the collision induced dissociation (CID). The pressure in the collision cell was approximately 2 mT. The collision energy was -10 eV for the quantitative ions and -15 eV for the confirmation ions. The electron multiplier, electron energy, and electron current were set at 1800 V, 200 eV, and 300 t~A, respectively. The electron lens voltage was 20 V. The source temperature was 150~ The scan rate was set at 0.02 s/scan. Acquisition was started at 3 min, and the retention time of SBMTE was about 5.56 min.
Analysis of urine for bis-mercapturate metabolite
Sample preparation. 1,1'-Sulfonylbis[2-S-(N-acetylcysteinyl)ethane] was synthesized by Defense Science and Technology Laboratory (Porton Down, Salisbury, U.K.) using a previously described procedure (13) . The sample preparation was similar to that published by Read and Black (8) except for a few minor changes. A 2-mL urine sample was spiked with 50 ng phenol red as an internal standard, acidified with 0.1 mL of 10% TFA in water, and applied to a 60 mg/3 mL Oasis HLB SPE cartridge that was preconditioned with methanol and 0.1% TFA in water. The SPE cartridge was then washed with 1 mL each of 0.1% TFA in water, 0.1% TFA in 5:95 methanol/water, and finally 0.1% TFA in 30:70 methanol/water. The cartridge was then dried under vacuum and eluted with 2 x 0.5 mL of 0.1% TFA in 60:40 methanol/water. The eluate was evaporated to dryness and redissolved in 0.2 mL of water for the liquid chromatography (LC)-MS-MS analysis. (8) 
LC-HS-HS. The LC-MS-MS analysis was similar to that published by Read and Black
Analysis of urine for nitrogen mustard HN1, HN2, and HN3 metabolites
The analysis for the metabolites of nitrogen mustards HN1, HN2, and HN3 [N-ethyldiethanolamine (EDEA), N-methyldiethanolamine (MDEA), triethanolamine (TEA), respectively] were analyzed as published by Lemire et al. (14) .
Analysis of urine for Lewisite metabolite
The metabolite of Lewisite L1 (2-chlorovinylarsonous acid or CVAA) was analyzed in human urine as reported by Wooten et al. (15) .
Results and Discussion
Urine samples from two individuals who had developed various degrees of blistering (9,10) after the destruction of a WWI era munition were tested to determine the cause of the vesi- cation. The samples were initially analyzed for metabolites of Lewisite L1; nitrogen mustard HN1, HN2, and HN3; and sulfur mustard HD. The results on both patients indicated that there were no detectable levels of CVAA (metabolite of Lewisite L1), EDEA (metabolite of HN1), and MDEA (metabolite of HN2) in urine. Levels for the nonspecific metabolite for HN3 (TEA) in urine were consistent with those found in the reference range of individuals with no suspected exposure to HN3 (14) . Detectable levels of the [~-lyase metabolites of HD were detected in the urine samples from the two patients. Figure 1 shows the chromatogram for the SBMTE from patient I two days after the exposure; the peaks are well above the noise levels and the confirmation ions are also clearly visible. Because no SBMTE was found in reference range studies (11, 12) with individuals with no known nor suspected exposure to HD, these results alone are considered unequivocal.
Several other metabolites in addition to the ~-lyase metabolites were measured to confirm the exposure of mustard agent HD including TDG, TDG-sulfoxide, and the HD bis-mercapturate. The results of the analysis of the [~-lyase metabolites, thiodiglycol, combined thiodiglycol and thiodiglycol sulfoxide, and the bis-mercapturate 1,1'-sulfonylbis[2-S-(N-acetylcysteinyl)ethane] for patient 1 (6.5% of body covered with blisters) from day 2 to day 11 after the exposure to sulfur mustard agent HD exposure are shown in Table I . The results of patient 2 (one small blister) for each of the urinary metabolites on days 2, 4, and 7 after exposure are also shown in Table I . The data are presented as both the volume-based concentrations and concentrations adjusted for creatinine content of the samples (16) .
The urinary excretion profile for the creatinine-corrected 13-1yase metabolites for patient 1 is shown in Figure 2 . This urinary concentration profile shows a common pattern for nonpersistent organic toxicants. There is a very rapid decrease in the amount of SBMTE over the first 4 or 5 days and then there is a long "tail" where the amount of SBMTE is excreted for several days at lower concentrations. The day 11 sample still showed a clear peak for the SBMTE that calculated to be 23 pg/mL but is below our statistical limit of detection of 38 pg/mL. The SBMTE values range from 23 lag/g creatinine (concentration 41 ng/mL) on the sample collected 2 days after exposure to 0.06 lag/g creatinine (0.023 ng/mL) on day 11. The half-life for the excretion of the [~-lyase metabolites in the patient was less than 1 day.
Patient 2 had much lower levels of SBMTE. All three samples had detectable levels of SBMTE (2.6, 0.85, and 0.084 ng/mL or 1.6, 0.31, and 0.04 lag/g creatinine, respectively). These measurements clearly showed exposure to mustard agent HD, and as was expected, the highest urinary level was in the first sample collected 2 days after exposure. Detectable levels of the [3-1yase metabolites were seen for 7 days after this relatively low level exposure to HD.
To further confirm the exposure, the hydrolysis products of HD were also measured. TDG was first measured in the urine samples followed by measuring both TDG + TDG-sulfoxide together after the reduction of TDG-sulfoxide in urine by TiCI 3. All the urine samples from patient 1 collected from days 2 through 11 showed detectable levels of TDG and TDG + TDGsulfoxide. Neither TDG nor TDG-sulfoxide are considered to be specific to only HD exposure because background levels of these compounds are found in the urine of individuals with no known exposure to mustard agent HD. In a previous study of individuals (11) with no known exposure to HD, the TDG + TDG-sulfoxide concentrations ranged from less than the level of detection (0.5 ng/mL) for 18% of the samples to between 10 and 20 ng/mL in 9% of the samples. The highest TDG + TDGsulfoxide level in the study of urine collected in the U.S. from individuals with no known exposure to HD was approximately 20 ng/mL. The levels of TDG alone were found to be less than 2.5 ng/mL in this same study on individuals with no known exposure to HD (11) . The results on patient 1, day 2 showed levels ofTDG + TDGsulfoxide of almost 50 ng/mL (28 1Jg/g creatinine) and TDG only of 24 ng/mL (14 ~g/g creatinine). These are higher than the levels that we have observed in individuals with no known HD exposure and are consistent with exposure to HD. On days 3 and 4 the TDG + TDG-sulfoxide levels were between 10-20 ng/mL and are in the range of those found in 9% of the individuals in our previous background level study. On days 5 and 6 the levels were again above 20 ng/mL (28 and 24 ng/mL or 26 and 21 lJg/g creatinine, respectively) again suggesting exposure to HD. The levels of TDG + TDG-sulfoxide fell to less than 15 ng/mL on day 7 and less than 10 ng/mL on days 8-11. These levels for TDG + TDG-sulfoxide were similar to background levels seen in people with no known HD exposure where almost 9% had levels between 10 and 20 ng/mL, 59% had levels between 2 and 10 ng/mL, 15% had levels between 0.5 and 2 ng/mL, and nearly 18% had TDG + TDG-sulfoxide levels less than 0.5 ng/mL. Thus, the TDG + TDG-sulfoxide levels on day 2 after the exposure and then again on days 5 and 6 were higher than we have seen in individuals with no known exposure to HD and are suggestive of HD exposure, but results of TDG + TDG-sulfoxide on other days were within the range of background levels found in the U.S. and would be much harder to interpret for confirmation of HD exposure.
The urinary concentration profiles for TDG and the combination of TDG + TDG-sulfoxide are much more complex than that of the [3-1yase metabolites. The creatinine corrected urinary concentration profile for both TDG and the combined TDG + TDG-sulfoxide for patient 1 are shown in Figure 3 . The TDG and the combined TDG + TDG-sulfoxide profiles were similar. The maximum urinary level was reached on day 2 after exposure. The urinary concentrations of TDG and TDG + TDGsulfoxide then dropped quickly over the next 2 days but then rose sharply on day 4. The urinary concentrations of TDG and TDG + TDG-sulfoxide remained high for the next 2 day s and then on day 7 both decreased sharply to commonly observed background levels (11) . This type of urinary concentration profile for TDG after exposure to HD has been reported previ- ously in both animal models and in humans (3, 17, 18) . The rise in urinary levels of TDG and its sulfoxide are thought to be from the hydrolysis of HD that, because of its lipophilic nature, becomes sequestered in adipose tissue, and also from the hydrolysis of unstable protein-mustard HD adducts (18) . Interestingly, in our previous study on TDG and TDG + TDG-sulfoxide levels in urine from individuals with no known or expected HD exposure, the ratio of TDG + TDG-sulfoxide/TDG were generally greater than 5. The urinary profiles of patient 1 showed ratios of TDG + TDG-sulfoxide/TDG ranged from 1.8 to 2.5 for the samples collected from day 2 to day 8 after the exposure. These results indicated that the levels of TDG and TDG-sulfoxide were approximately equal in the patients who had been exposed to HD compared to individuals with no suspected exposure to HD, whereas the amount of TDG-sulfoxide was almost always higher. The similarity of levels of TDG and TDG-sulfoxide may be indicative of recent exposure to HD rather than endogenous amounts of TDG but these are only observations on a single patient and may not be universal. On days 8-11, when the levels of both TDG and TDG-sulfoxide in the urine of patient 1 fell to levels commonly seen in the background levels in the U.S., the ratio of TDG + TDG-sulfoxide to TDG rose to between 3 and over 5. Although the ratio of TDG + TDG-sulfoxide to TDG is by no means conclusive of higher level exposure to mustard agent HD, it does appear that nearly equal proportions of TDG and TDG-sulfoxide may be useful in suggesting recent exposure to HD.
Patient 2 did not show high levels of TDG + TDG-sulfoxide or any detectable levels of TDG. The concentrations of TDG + TDG-sulfoxide on both day 2 and day 4 after the low-level HD exposure were approximately 1.1 pg/g of creatinine (1.8 and 3.0 ng/mL, respectively). The urinary levels of TDG + TDG-sulfoxide rose slightly to 2.3 lJg/g of creatinine (4.4 ng/mL) on day 7 after exposure. These concentrations of TDG + TDG-sulfoxide are consistent with those found in individuals with no suspected exposure to HD (11) and would not be useful to confirm this low-level HD exposure. The levels of the bismercapturate metabolite of mustard sulfone were also measured. The levels of the bismercaptutate were much lower than those from the hydrolysis products of HD or the Ig-lyase metabolites. The levels of the bismercapturate of mustard sulfone for the day 2 sample from patient 1 were 3.1 ng/mL. By day 3, the levels of the bismercapturate of HD were below the limit of detection of 1 ng/mL. Additional samples were not measured after the first non-detectable sample.
Conclusions
Analysis of urine samples collected from two individuals after exposure to a vesicant confirmed the exposure was sulfur mustard. Several urinary metabolites were measured. Samples collected over multiple days not only determined the exposure was due to sulfur mustard, but also yielded some insights into the relative amounts of each of the metabolites that are present after a relatively high exposure (6.5% blistering of total body surface area) and a lower level exposure of HD. These data will also help us to better determine which metabolites are most useful to confirm a HD exposure, to understand how quickly a sample must be collected for each metabolite, and may begin to help us understand the correlation of metabolite levels and the health outcomes.
These data suggest that the [3-1yase metabolites of HD are the best indicators of exposure to HD because they are specific to HD, formed in relatively high concentrations as compared to the other metabolites, and persist in the urine for several days. The half-life of the SBMTE metabolites in these two patients was less than ] day. Patient I had SBMTE levels of 41 ng/mL on day 2 after the exposure and these dropped to 0.023 ng/mL on day 11. The levels of patient 2 with only one small blister were 2.6 ng/mL on day 2 and dropped to 0.084 ng/mL on day 7. Thus, we were able to detect exposure of an individual who showed minimal symptoms from dermal exposure to HD by measuring SBMTE in urine samples taken 7 days after exposure. Detection of high levels of the hydrolysis products TDG and TDG-sulfoxide were useful to confirm the exposure to HD. Because the levels of TDG and the sulfoxide were high in early samples taken from the highly exposed patient but quickly dropped to within the range found for individuals with no known exposure to HD, TDG and TDG-sulfoxide are not useful to unequivocally prove an exposure to HD, but they are useful to give further information to help confirm an exposure. Interestingly, the ratio of the total of TDG + TDG-sulfoxide to TDG was much lower than the ratio seen in individuals with no known exposure to HD. Thus, this ratio of TDG + TDG-sulfoxide to TDG may be useful to suggest a recent exposure to HD, but this change in ratio is only an observation on a single patient. The bismercapturate of HD is also considered to be a specific metabolite for HD. Levels of the bismercapturate were much lower than those of the I~-lyase metabolites or the hydrolysis products. These data indicate that the I~-]yase metabolites of HD are the most selective and sensitive indicators in urine samples to confirm HD exposure and determine the extent of the exposure.
